X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Ubiquigent will deploy its DUB-focused platform, combined with its deep understanding of the DUB field, to develop novel target engagement assays to support Debio-0432, small molecule USP-1 inhibitor, as it approaches the clinic.
Lead Product(s): Debio-0432
Therapeutic Area: Oncology Product Name: Debio-0432
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Ubiquigent
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 26, 2024
Details:
Debio 0123, an oral, potent, highly selective, and brain-penetrant WEE1 inhibitor is being evaluated in Phase I clinical trial studies for patients with advanced solid tumors.
Lead Product(s): Debio 0123
Therapeutic Area: Oncology Product Name: Debio 0123
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
The collaboration aims to support TransCode’s lead therapeutic candidate, TTX-MC138, which utilizes antisense technology in the treatment of metastatic cancer. Currently, it is undergoing assessment in an early-stage clinical trial.
Lead Product(s): TTX-MC138
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: TransCode Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 29, 2024
Details:
Under the licensing agreement, SunRock will concentrate on the clinical development of SRB19 using Debiopharm’s Multilink technology to create an improved HER3-EGFR bispecific antibody-drug conjugate for treating head and neck cancer.
Lead Product(s): SRB19
Therapeutic Area: Oncology Product Name: SRB19
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: SunRock Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2024
Details:
The collaboration will explore the synergy between Debio 0123, a potential best-in-class, brain-penetrant, and highly selective WEE1 inhibitor, and RP-6306 (lunresertib), a first-in-class, selective and potent oral, small molecule inhibitor of PKMYT1 with anticancer activity.
Lead Product(s): Debio 0123,Lunresertib
Therapeutic Area: Oncology Product Name: Debio 0123
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Repare Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
Under the agreement, Debiopharm will boost its ADC oncology pipeline through SunRock’s antibody portfolio, including SRB21, an anti-HER3-HER2 bispecific, integrating Debiopharm’s Multilink™ & AbYlink™ technologies to create innovative antibody drug conjugates (ADCs).
Lead Product(s): SRB21
Therapeutic Area: Oncology Product Name: SRB21
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: SunRock Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 21, 2023
Details:
Debio 0123 is a brain-penetrant, highly selective WEE1 kinase inhibitor combines with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC).
Lead Product(s): Debio 0123,Etoposide,Carboplatin
Therapeutic Area: Oncology Product Name: Debio 0123
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
Debio 0123 is a brain-penetrant and highly selective WEE1 inhibitor, it is being investigated in combination with temozolomide (TMZ) in patients with recurrent or progressive glioblastoma and in combination with TMZ/RT (SOC) in newly diagnosed patients.
Lead Product(s): Debio 0123,Temozolomide
Therapeutic Area: Oncology Product Name: Debio 0123
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Debio 0328 ([68Ga]Ga-DPI-4452) and Debio 0228 ([177Lu]Lu-DPI-4452) are the only peptide-based theranostic pair targeting CAIX in clinical development, with pan-tumor potential, and developed first for patients with advanced cancers such as renal, pancreatic, and colorectal.
Lead Product(s): [68Ga]Ga-DPI-4452,[177Lu]Lu-DPI-4452
Therapeutic Area: Oncology Product Name: Debio 0328
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
Debiopharm obtains global rights from Novo Nordisk for the development of FT-3171, a small molecule (ubiquitin-specific protease 1) USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway.
Lead Product(s): FT-3171
Therapeutic Area: Oncology Product Name: FT-3171
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Novo Nordisk
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 02, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
